Wisconsin Assembly passes capital investment bill, revised CAPCO program not presented
MADISON - The Wisconsin Assembly passed a bill Friday designed to promote capital investment and technological entrepreneurship by means of tax credits, grants and loans. The legislation, , was only one of two venture capital-oriented bills co-authored by Sen. Ted Kanavas, R-Brookfield, to hit the Assembly...Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
Researchers from American College of Chest Physicians (ACCP) had provided clinical guidelines for chest physicians who deal with prevention and management of postoperative atrial fibrillation (AF) after cardiac surgery. Their report was published in the latest issue of journal Chest. The researchers offer specific guidelines relating to cardiac pacing, anticoagulation therapy // , pharmac...ADHD Treatment -Phase 3 data on Lisdexamfetamine dimesylate Presented
The investigational ADHD treatment, lisdexamfetamine dimesylate (also known as NRP104 or LDX) by Shire plc and its collaborative partner// New River Pharmacuticals has yielded a good response in children with Attention Deficit Hyperactivity Disorder, it was announced today. The data was presented at a national meeting of child and adolescent psychiatrists last weekend. The...Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
LUGANO, Switzerland--(BUSINESS WIRE)--Jul 9, 2007 - ZIOPHARMOncology, Inc. (NASDAQ: ZIOP) announces that positive interim datafrom an ongoing phase II trial of ZIO-201 (isophosphoramide mustard- IPM) to treat advanced sarcoma patients was presented at theEuropean Society of Medical Oncology (ESMO) meeting held July 5-8,2007 in Lugano, Switzerland. The abstract entitled, "Phase-I/IIStudy of...Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Jul 3, 2007 - NymoxPharmaceutical Corporation (NASDAQ: NYMX) today announced thatfurther clinical results from the Company's studies of NX-1207 forbenign prostatic hyperplasia (BPH) will be presented at the NewEngland Section of the American Urological Association Meeting inBoston in September. The paper is authored by leading clinicalresearch inves...